Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T
How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?
16 Elo 201823min
Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers
Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?
9 Elo 201821min
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest
What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Lu...
2 Elo 201823min
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
26 Heinä 201824min
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season
Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.
19 Heinä 201825min
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?
12 Heinä 201824min
Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts
Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.
5 Heinä 201819min
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.
28 Kesä 201823min
